These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 9763353)

  • 41. Prevalence of factor V Leiden and G6PD 1311 silent mutations in Dalmatian population.
    Cikes V; Abaza I; Krzelj V; Terzić IM; Tafra R; Trlaja A; Marusić E; Terzić J
    Arch Med Res; 2004; 35(6):546-8. PubMed ID: 15631882
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Activated protein c resistance (APC) and inherited factor V (FV) mis-sense mutation in patients with venous and arterial thrombosis in a haematology clinic.
    Ma DD; Aboud MR; Williams BG; Isbister JP
    Aust N Z J Med; 1995 Apr; 25(2):151-4. PubMed ID: 7605298
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Resistance to activated protein C and FV leiden mutation in patients with a history of acute myocardial infarction or primary hypertension.
    Makris TK; Krespi PG; Hatzizacharias AN; Gialeraki AE; Anastasiadis G; Triposkiadis FK; Mandalaki T; Kyriakidis MK
    Am J Hypertens; 2000 Jan; 13(1 Pt 1):61-5. PubMed ID: 10678272
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Venous thrombosis in older people: prevalence of the factor V gene mutation Q506.
    André E; Siguret V; Alhenc-Gelas M; Saint-Jean O; Gaussem P
    J Am Geriatr Soc; 1998 Dec; 46(12):1545-9. PubMed ID: 9848816
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Acquired activated protein C resistance is common in cancer patients and is associated with venous thromboembolism.
    Haim N; Lanir N; Hoffman R; Haim A; Tsalik M; Brenner B
    Am J Med; 2001 Feb; 110(2):91-6. PubMed ID: 11165549
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Factor V Leiden gene mutation in three South African families.
    Rubinstein R; Bowers D; Novitzky N; Louw I; Jacobs P
    S Afr Med J; 1999 Feb; 89(2):176. PubMed ID: 10191872
    [No Abstract]   [Full Text] [Related]  

  • 47. Activated protein C resistance assay and factor V Leiden.
    Prüller F; Weiss EC; Raggam RB; Cervar-Zivkovic M; Renner W; Wagner J; Michaelis S; März W; Mangge H
    N Engl J Med; 2014 Aug; 371(7):685-6. PubMed ID: 25119624
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Activated protein C resistance and factor V Leiden: a review.
    Rosendorff A; Dorfman DM
    Arch Pathol Lab Med; 2007 Jun; 131(6):866-71. PubMed ID: 17550313
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Factor V gene mutation causing inherited resistance to activated protein C as a basis for venous thromboembolism.
    Dahlbäck B
    J Intern Med; 1995 Mar; 237(3):221-7. PubMed ID: 7891043
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Epidemiology of factor V Leiden: clinical implications.
    De Stefano V; Chiusolo P; Paciaroni K; Leone G
    Semin Thromb Hemost; 1998; 24(4):367-79. PubMed ID: 9763354
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Factor V Leiden and FII 20210 testing in thromboembolic disorders.
    Pajič T
    Clin Chem Lab Med; 2010 Dec; 48 Suppl 1():S79-87. PubMed ID: 21091236
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Co-segregation of thrombosis with the factor V Q506 mutation in an extended family with resistance to activated protein C.
    Beufé S; Borg JY; Vasse M; Charbonnier F; Moreau V; Monconduit M; Frebourg T
    Br J Haematol; 1995 Mar; 89(3):659-62. PubMed ID: 7734374
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Resistance to activated protein C, the FV:Q506 allele, and venous thrombosis.
    Dahlbäck B; Hillarp A; Rosen S; Zöller B
    Ann Hematol; 1996 Apr; 72(4):166-76. PubMed ID: 8624369
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Obstetric implications of activated protein C resistance and factor V Leiden mutation.
    Gherman RB; Goodwin TM
    Obstet Gynecol Surv; 2000 Feb; 55(2):117-22. PubMed ID: 10674255
    [TBL] [Abstract][Full Text] [Related]  

  • 55. FV and APC resistance: the plot thickens.
    Castoldi E
    Blood; 2014 Apr; 123(15):2288-9. PubMed ID: 24723678
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Factor V Leiden in an Urartian, dating back to 1000 BC.
    Alakoç YD; Aka PS; Eğin Y; Akar N
    Clin Appl Thromb Hemost; 2010 Dec; 16(6):679-83. PubMed ID: 19617246
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Resistance to activated protein C and ischemic arterial disease in a young man.
    Menezes IA; Romani RF; Aoki YS; Abdo JC; Carvalho M
    Arq Bras Cardiol; 2010 Mar; 94(3):e31-3, e91-3. PubMed ID: 20730250
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Resistance to activated protein C due to factor V Leiden mutation: high prevalence in patients with post-thrombotic leg ulcers.
    Gaber Y; Siemens HJ; Schmeller W
    Br J Dermatol; 2001 Mar; 144(3):546-8. PubMed ID: 11260012
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Population study of the G1691A mutation (R506Q, FV Leiden) in the human factor V gene that is associated with resistance to activated protein C.
    Braun A; Müller B; Rosche AA
    Hum Genet; 1996 Feb; 97(2):263-4. PubMed ID: 8566967
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Activated protein C resistance: the most common risk factor for venous thromboembolism.
    Sheppard DR
    J Am Board Fam Pract; 2000; 13(2):111-5. PubMed ID: 10764192
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.